P-243Phase II study of third-line panitumumab rechallenge in patients with metastatic wild-type KRAS colorectal cancer who achieved a clinical benefit in response to first-line panitumumab plus chemotherapy. (20th June 2018) - Tsuji, A; Nakamura, M; Watanabe, T; Manaka, D; Matsuoka, H; Kataoka, M; Takeuchi, M; Ichikawa, W; Fujii, M